PubMed ID:
21831969
Public Release Type:
Journal
Publication Year: 2011
Affiliation: Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado, USA. liping.yu@ucdenver.edu
DOI:
https://doi.org/10.2337/db11-0674
Authors:
Bundy B,
Eisenbarth GS,
Herold K,
Krause-Steinrauf H,
Krischer J,
McGee PL,
Pugliese A,
Type 1 Diabetes TrialNet Anti-CD20 Study Group,
Yu L
Studies:
TrialNet
The TrialNet Study Group evaluated rituximab, a B-cell-depleting monoclonal antibody, for its effect in new-onset patients with type 1A diabetes. Rituximab decreased the loss of C-peptide over the first year of follow-up and markedly depleted B lymphocytes for 6 months after administration. This article analyzes the specific effect of rituximab on multiple islet autoantibodies.